EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSOCUG00000011599
Gene Symbol: CACNA1C
2 Cross references
211 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSOCUG00000013474
Gene Symbol: CACNA1D
2 Cross references
281 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSOCUG00000005231
Gene Symbol: CACNA1F
2 Cross references
178 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSOCUG00000002733
Gene Symbol: CACNA1G
2 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSOCUG00000003619
Gene Symbol: CACNA1S
2 Cross references
259 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSOCUG00000026372
Gene Symbol: CNR2
2 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSOCUG00000004632
Gene Symbol: CA12
3 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSOCUG00000007328
Gene Symbol: CA13
3 Cross references
288 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSOCUG00000009032
Gene Symbol: CA14
3 Cross references
210 Possible Orthologues:

Carbonic Anhydrase 2

Ensembl ID : ENSOCUG00000011742
Gene Symbol: CA2
3 Cross references
282 Possible Orthologues:

Carbonic Anhydrase 3

Ensembl ID : ENSOCUG00000011736
Gene Symbol: CA3
2 Cross references
307 Possible Orthologues:

Carbonic Anhydrase 5b

Ensembl ID : ENSOCUG00000005571
Gene Symbol: CA5B
2 Cross references
179 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).